MA34310B1 - Procédé pour la préparation d'une composition pharmaceutique contenant un transporteur d'oxygène thermostable - Google Patents

Procédé pour la préparation d'une composition pharmaceutique contenant un transporteur d'oxygène thermostable

Info

Publication number
MA34310B1
MA34310B1 MA35457A MA35457A MA34310B1 MA 34310 B1 MA34310 B1 MA 34310B1 MA 35457 A MA35457 A MA 35457A MA 35457 A MA35457 A MA 35457A MA 34310 B1 MA34310 B1 MA 34310B1
Authority
MA
Morocco
Prior art keywords
cancer
hemoglobin
heat treatment
tetrameric hemoglobin
tumor
Prior art date
Application number
MA35457A
Other languages
English (en)
Inventor
Bing Lou Wong
Sui Yi Kwok
Original Assignee
Bing Lou Wong
Sui Yi Kwok
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/821,214 external-priority patent/US20110319858A1/en
Priority claimed from US12/957,430 external-priority patent/US7932356B1/en
Application filed by Bing Lou Wong, Sui Yi Kwok filed Critical Bing Lou Wong
Publication of MA34310B1 publication Critical patent/MA34310B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention porte sur une hémoglobine tétramère non polymère réticulée hautement purifiée et thermostable destinée à être utilisée chez des mammifères sans provoquer de lésion rénale et de vasoconstriction. Une étape de traitement thermique à haute température et sur une courte durée (HTST) est effectuée pour enlever la forme dimère non souhaitée de l'hémoglobine, l'hémoglobine tétramère non réticulée non souhaitée et les impuretés protéiques plasmatiques non souhaitées de façon efficace. L'ajout de N-acétylcystéine après traitement thermique et éventuellement avant traitement thermique maintient un faible niveau de méthémoglobine. L'hémoglobine tétramère réticulée thermostable permet d'améliorer et de prolonger l'oxygénation dans un tissu normal et hypoxique. Dans un autre aspect, le produit est utilisé dans le traitement de divers types de cancer tels que la leucémie, le cancer colorectal, le cancer du poumon, le cancer du sein, le cancer du foie, le carcinome du nasopharynx et le cancer de l'Ssophage. L'hémoglobine tétramère de l'invention peut également être utilisée pour empêcher la métastase tumorale et la récidive de tumeur après excision chirurgicale de tumeur. En outre, l'hémoglobine tétramère de l'invention peut être administrée à des patients avant chimiothérapie et radiothérapie.
MA35457A 2010-06-23 2011-04-15 Procédé pour la préparation d'une composition pharmaceutique contenant un transporteur d'oxygène thermostable MA34310B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US12/821,214 US20110319858A1 (en) 2010-06-23 2010-06-23 Method for the preparation of a heat stable oxygen carrier-containing pharmaceutical compositions and the use thereof
US12/957,430 US7932356B1 (en) 2010-06-23 2010-12-01 Method for the preparation of a heat stable oxygen carrier-containing pharmaceutical composition
US13/013,850 US20110319332A1 (en) 2010-06-23 2011-01-26 Treatment methods using a heat stable oxygen carrier-containing pharmaceutical composition
PCT/US2011/032595 WO2011162863A1 (fr) 2010-06-23 2011-04-15 Procédé pour la préparation d'une composition pharmaceutique contenant un transporteur d'oxygène thermostable

Publications (1)

Publication Number Publication Date
MA34310B1 true MA34310B1 (fr) 2013-06-01

Family

ID=45353097

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35457A MA34310B1 (fr) 2010-06-23 2011-04-15 Procédé pour la préparation d'une composition pharmaceutique contenant un transporteur d'oxygène thermostable

Country Status (9)

Country Link
US (1) US20110319332A1 (fr)
CN (2) CN103421109B (fr)
AP (1) AP3080A (fr)
CL (1) CL2012003523A1 (fr)
EA (1) EA023689B1 (fr)
HK (2) HK1166719A1 (fr)
MA (1) MA34310B1 (fr)
MX (1) MX2012000592A (fr)
WO (1) WO2011162863A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8048856B1 (en) * 2010-06-23 2011-11-01 Billion King, Ltd. Treatment methods using a heat stable oxygen carrier-containing pharmaceutical composition
US20130052232A1 (en) * 2011-08-31 2013-02-28 Bing Lou Wong Method for the preparation of a heat stable oxygen carrier-containing composition facilating beta-beta cross-linking
US20140106004A1 (en) * 2012-10-12 2014-04-17 Bing Lou Wong Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence
CN103251998B (zh) * 2012-11-08 2015-09-02 亿京国际有限公司 用于血红蛋白氧载体(hboc)溶液的精确输注递送系统
WO2015179657A1 (fr) * 2014-05-22 2015-11-26 University Of Maryland, Baltimore Traitement du cancer et inhibition de métastases à l'aide de sous-unité bêta de l'hémoglobine
CN107406816B (zh) * 2014-07-31 2021-10-12 马里兰大学巴尔的摩分校 用于从人类血液制造蛋白质的微量生物处理系统和方法
CN105497894B (zh) * 2015-12-21 2019-01-04 中国科学院深圳先进技术研究院 用于肿瘤光动力治疗的血红蛋白-光敏剂试剂及其应用
CN108117591A (zh) * 2016-11-30 2018-06-05 北京大学 一种用于癫痫诊断的生物标记物
CN114341174B (zh) * 2019-08-29 2024-05-17 亿京国际有限公司 硫代琥珀酰基交联的血红蛋白类似物及其使用和制备方法
CN110499287B (zh) * 2019-08-30 2021-07-23 博雅干细胞科技有限公司 简易制备胎盘间充质干细胞外泌体的方法
CN110642941A (zh) * 2019-11-12 2020-01-03 武汉光谷新药孵化公共服务平台有限公司 一种人血红蛋白的制备方法
CN113621055B (zh) * 2021-08-23 2023-05-02 山东仙普爱瑞科技股份有限公司 一种抗菌和抗病毒的猪血红蛋白β链C端片段、表达该片段的枯草芽孢杆菌、制剂以及应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5387672A (en) * 1993-03-02 1995-02-07 The University Of Maryland At Baltimore Hemoglobin intramolecularly cross-linked withlong chain divalent reagents
US5952470A (en) * 1995-06-07 1999-09-14 Biopure Corporation Method for separating unmodified hemoglobin from cross-linked hemoglobin
US5741894A (en) * 1995-09-22 1998-04-21 Baxter International, Inc. Preparation of pharmaceutical grade hemoglobins by heat treatment in partially oxygenated form
US7504377B2 (en) * 2006-10-23 2009-03-17 Ikor, Inc. Nitric oxide-blocked cross-linked tetrameric hemoglobin

Also Published As

Publication number Publication date
EA201101155A1 (ru) 2012-07-30
MX2012000592A (es) 2012-02-22
CL2012003523A1 (es) 2014-02-14
CN103421109A (zh) 2013-12-04
WO2011162863A1 (fr) 2011-12-29
WO2011162863A8 (fr) 2012-04-19
HK1166719A1 (en) 2012-11-09
CN102510753A (zh) 2012-06-20
HK1191028A1 (zh) 2014-07-18
AP2012006230A0 (en) 2012-04-30
AP3080A (en) 2015-01-31
US20110319332A1 (en) 2011-12-29
EA023689B1 (ru) 2016-07-29
CN103421109B (zh) 2016-01-27
CN102510753B (zh) 2013-07-24

Similar Documents

Publication Publication Date Title
MA34310B1 (fr) Procédé pour la préparation d'une composition pharmaceutique contenant un transporteur d'oxygène thermostable
MA35279B1 (fr) Composition pharmaceutique contenant un transporteur d'oxygène thermostable pour différentes applications de traitement
Salinas Cisneros et al. Recent advances in the treatment of sickle cell disease
MY155598A (en) A method for the preparation of a heat stable oxygen carrier-containing pharmaceutical composition
WO2011149602A8 (fr) Composition pharmaceutique contenant un substitut sanguin stable à haute température
Westerterp et al. Regulation of hematopoietic stem and progenitor cell mobilization by cholesterol efflux pathways
Grønbæk et al. Alterations of the MMAC1/PTEN gene in lymphoid malignancies
Alvey et al. Engineering macrophages to eat cancer: from “marker of self” CD47 and phagocytosis to differentiation
Kumaresan et al. Multifunctional murrel caspase 1, 2, 3, 8 and 9: Conservation, uniqueness and their pathogen-induced expression pattern
Mercher et al. Pediatric acute myeloid leukemia (AML): from genes to models toward targeted therapeutic intervention
MA35358B1 (fr) Procede permettant de preparer une composition contenant un transporteur d'oxygene thermostable.
Xie et al. Teleost antimicrobial peptide hepcidin contributes to host defense of goldfish (Carassius auratus L.) against Trypanosoma carassii
Stankovic Stojanovic et al. Chronic myeloid leukaemia and sickle cell disease: could imatinib prevent vaso-occlusive crisis?
Cisneros et al. Research in sickle cell disease: from bedside to bench to bedside
Cortés et al. Indoleamine 2, 3-dioxygenase: First evidence of expression in rainbow trout (Oncorhynchus mykiss)
Wang et al. E2F1 hinders skin wound healing by repressing vascular endothelial growth factor (VEGF) expression, neovascularization, and macrophage recruitment
Li et al. A novel oxygen carrier “YQ23” suppresses the liver tumor metastasis by decreasing circulating endothelial progenitor cells and regulatory T cells
Lu et al. Anti-triple-negative breast cancer metastasis efficacy and molecular mechanism of the STING agonist for innate immune pathway
JP2011506489A (ja) 止血をモジュレートする組成物およびその使用法
Chen et al. Histone deacetylase inhibitors Trichostatin A and MCP30 relieve benzene-induced hematotoxicity via restoring topoisomerase IIα
Moncure et al. Heme-oxygenase-1 mRNA expression affects hemorrhagic shock-induced leukocyte adherence
Gulevskyy et al. CURRENT CONCEPT OF THE STRUCTURAL AND FUNCTIONAL PROPERTIES OF ALFA-FETOPROTEIN AND THE POSSIBILITIES OF ITS CLINICAL APPLICATION
Lee et al. Comparative analysis of del Nido cardioplegia versus blood cardioplegia in isolate coronary artery bypass grafting
Yuan et al. The type 2 cannabinoid receptor regulates the severity of acute and chronic graft versus host disease in mice
Li et al. Unraveling the Role of TP53 in Colorectal Cancer Therapy: From Wild-Type Regulation to Mutant